Agilon Health (NYSE:AGL) Bolsa

AGILON HEALTH INC

Agilon Health

Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAMI

ACEL

AXON

CDNA

CLIK

ENVB

FLYW

HCTI

ICCT

LBTYK

LMND

NAMS

PITA

PRCH

SMCI

ZoomInfo sorprende con resultados mejores de lo esperado y sus acciones suben un 19,6%. Descubre qué otras acciones se están moviendo hoy.

Acciones de ZoomInfo se disparan un 20%; 20 acciones que se están moviendo en el premercado de EE.UU.

Agilon Health Inc

T2 Metals Corp

Adventure Gold - United States Dollar

AUSTRAL GOLD LTD ORD by Austral Gold Ltd.

Austral Gold Ltd

ANGELALIGN TECH INC by Angelalign Technologies Inc.

Angelalign Technology Inc

AGL Energy Ltd

AGILITY CAPITAL HOLDING by AGILITY CAPITAL HOLDING INC.

Agility Capital Holding Inc

ANGEL TELECOM CORP by Angel Telecom Corp.

AgileThought Inc

ATLANTIS GLORY INC by Atlantis Glory Inc.

Atlantis Glory Inc

Mueller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>) has outperformed the market over the past 20 years by 4.47% on an annualized basis producing an average annual return of 12.96%. Currently, Mueller Industries has a market capitalization of $8.77 billion. 
Buying $1000 In MLI: If an investor had bought $1000 of MLI stock 20 years ago, it would be worth $11,436.43 today based on a price of $79.28 for MLI at the time of writing.
<h3>Mueller Industries's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751035513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Barclays analyst Lauren Lieberman maintains Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) with a Overweight and lowers the price target from $38 to $37.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Keurig Dr Pepper, Lowers Price Target to $37

Ostin Technology Group Co., Ltd. ("the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>), a leading supplier of display modules and polarizers based in China, issued the following statement in response to the market activity on June 26:
The Company does not have any undisclosed material matters, nor is it aware of the specific reasons for the abnormal stock price fluctuations on June 26. However, we must caution investors and all other persons to rely solely on statements and filings with the U.S. Securities and Exchange Commission issued by the Company itself or its authorized representatives. The Company does not intend to make further statements regarding this matter.

Ostin Technology Responds To Unusual Stock Activity, Says "The Company Does Not Have Any Undisclosed Material Matters, Nor Is It Aware Of The Specific Reasons For The Abnormal Stock Price Fluctuations On June 26"

BioCryst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) agrees to sell its European Orladeyo (berotralstat) business to Neopharmed Gentili for up to $264 million.
Orladeyo (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older.
One capsule of Orladeyo per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
BioCryst plans to use the proceeds from the transaction to retire all remaining term debt ($249 million) from Pharmakon, which will eliminate approximately $70 million of future interest payments.
The company now expects to end 2027 with approximately $700 million in cash and no term debt, an increase of $400 million from the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46135746/biocryst-announces-sale-of-european-orladeyo-berotralstat-business-to-neopharmed-gentili-for-up-to" rel="noreferrer noopener">prior 2027 net cash guidance</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45209967/biocryst-pharmaceuticals-soars-23-in-one-session-heres-why-it-surprised-investors" rel="noreferrer noopener">BioCryst Pharmaceuticals Soars 23% In One Session &#8211; Here&#8217;s Why It Surprised Investors</a>
&#8220;This transaction is consistent with our strategy of making Orladeyo available to patients in Europe through the team we built, and it now provides the capital to retire our remaining term debt, leaving us with a significantly higher margin business. Our increased profitability puts us in an even stronger position to create value well into the next decade through sustainable Orladeyo growth, our pipeline, and potential external opportunities,&#8221; said Jon Stonehouse, president and CEO of BioCryst.
Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and up to $14 million in future milestones associated with sales in Central and Eastern Europe.
Neopharmed Gentili is acquiring BioCryst&#8217;s European organization, enabling commercial continuity for Orladeyo and resulting in at least $50 million in expected annual operating expense savings to BioCryst.
Neopharmed Gentili will be responsible for all royalties related to European sales in the territory.
European Orladeyo revenues will still be credited to BioCryst in determining global royalty tiers (no royalty due on global revenues &gt;$550 million) and count towards the cap on the OMERS royalty.
Earlier in June, BioCryst announced that following a positive recommendation from the Zorginstituut Nederland, Orladeyo (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older.
The reimbursement approval in the Netherlands marks national reimbursement for Orladeyo across all <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45810241/biocryst-achieves-reimbursement-for-orladeyo-across-all-major-european-countries" rel="noreferrer noopener">major European countries</a>.
Price Action: BCRX stock is down 1.4% at $9.52 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/46137803/apogees-ceo-expects-to-mitigate-tariffs-later-this-year-lifts-forecast" target="_blank" rel="noreferrer noopener">Apogee&#8217;s CEO Expects To Mitigate Tariffs Later This Year, Lifts Forecast</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

BCRX

BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering

Goldman Sachs analyst Alexander Blostein downgrades AllianceBernstein Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) from Buy to Neutral and lowers the price target from $42.25 to $40.

Downgrades

Goldman Sachs Downgrades AllianceBernstein Holding to Neutral, Lowers Price Target to $40

Macro Economic Events

Politics

Global

Economics

EU And U.S. Confident They'll Reach Tariff Deal By July Deadline

WIIM

AOUT

AOUT stock has given up its prior gain. American Outdoor Brands shares were trading higher after the company reported better-than-expected Q4 financial results.

INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) stock is trading higher on Friday, with a session volume of 10.26 million compared to the average volume of 519.5K, <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">per data from Benzinga Pro</a>.
On Thursday,  INmune Bio said it will host a conference call on Monday, June 30, to present topline data from the Phase 2 MINDFuL trial in early <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Alzheimer&#8217;s disease</a>.
The MINDFuL study investigates XPro in patients with mild cognitive impairment or Alzheimer's disease with brain inflammation.
The MINDFuL study <a href="https://inmunebio.com/index.php/clinical-trials/mindful-section" target="_blank" rel="noreferrer noopener">will</a> compare XPro to placebo (an injection that looks like the investigational drug but does not contain active medicine) to determine whether XPro affects memory, functioning and behavior, and whether it is safe and tolerable.
In November 2024, INmune Bio completed randomization of patients for <a href="https://www.benzinga.com/pressreleases/24/11/g41939489/inmune-bio-inc-announces-final-enrollment-of-208-patients-in-phase-2-trial-in-early-alzheimers-dis" target="_blank" rel="noreferrer noopener">its Phase 2 trial</a>. &#8220;The trial ended up overenrolled with a total of 208 patients, 56% of whom were categorized as mild AD and 44% as MCI,&#8221; said RJ Tesi, CEO of INmune Bio
In September 2024, the company announced that the results of an additional analysis of blinded data from its AD02 Phase II Alzheimer&#8217;s Disease trial demonstrated&nbsp;exceptional performance of the novel cognitive measure EMACC and a highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40897550/inmune-bio-announces-results-of-additional-blinded-interim-analysis-of-phase-2-alzheimers-disease-" rel="noreferrer noopener">accepted endpoint for AD trials.</a>
Key Findings: An independent review confirmed a highly significant correlation (p&lt;0.001) between baseline scores on EMACC and CDR-SB, the secondary endpoint in the AD02 trial.
The correlation of EMACC, when measured during the screening process and again at the first study visit before treatment, was found to be 0.93.
The difference in EMACC performance between patients with CDR global ratings of 0.5 (prodromal AD) and those rated 1.0 (mild dementia) was very large, with an effect size (Cohen&#8217;s d) of 0.87 (p&lt;.0001)
XPro is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors.
XPro could have potential substantial beneficial effects in patients with neurologic disease by <a href="https://www.benzinga.com/pressreleases/25/06/g46127038/inmune-bio-inc-to-announce-top-line-results-from-mindful-phase-2-trial-in-early-alzheimers-on-mond" target="_blank" rel="noreferrer noopener">decreasing neuroinflammation</a>.
INMB Price Action: INMB stock is up 74.68% at $10.97 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/46138385/deal-dispatch-darden-bahama-breeze-nba-ma-heats-up" target="_blank" rel="noreferrer noopener">Deal Dispatch: Darden Cools On Bahama Breeze, NBA M&amp;A Heats Up</a></li>
</ul>
Photo: khunkornStudio via Shutterstock

INMB

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

<a href="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/">https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/</a>

'US Supreme Court preserves key element of Obamacare preventive care'- Reuters

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is exploring the acquisition of voice-cloning <a href="https://www.benzinga.com/topic/artificial-intelligence" target="_blank" rel="noreferrer noopener">artificial intelligence startup</a> PlayAI and some of its employees.
Financial terms of the transaction remain undisclosed, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-06-26/meta-in-talks-to-buy-ai-voice-startup-playai-in-push-for-talent?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">reported</a> on Thursday, citing unnamed sources familiar with the matter.
The move marks Meta&#8217;s plan to build a &#8220;superintelligence&#8221; lab to unlock value. The update coincided with growing competition in the AI voice assistant space. 
In March, OpenAI&nbsp;updated its&nbsp;ChatGPT&nbsp;voice assistant to make it more <a target="_blank" href="https://www.benzinga.com/tech/25/03/44468019/openai-says-its-making-chatgpt-voice-assistant-sound-more-like-a-human-and-it-wont-interrupt-as-much" rel="noreferrer noopener">personable and responsive</a>.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a>
Also in March, <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44401097/soundhound-ai-integrates-nvidias-software-to-accelerate-voice-ai-technologies" rel="noreferrer noopener">conversational AI solutions</a> provider&nbsp;SoundHound AI&nbsp;expanded its partnership&nbsp;with&nbsp;Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to enhance the speed and efficiency of its AI-driven solutions.
In June, the parent company of Facebook and Instagram invested $14.3 billion in <a href="https://www.benzinga.com/markets/tech/25/06/45880561/meta-on-the-verge-of-a-15-billion-deal-with-scale-ai-report" target="_blank" rel="noopener">data-labeling startup</a> Scale AI and tapped its CEO to lead its AI team.
Meta CEO Mark Zuckerberg had tapped AI researchers from Google, Sesame AI, and OpenAI for its AI team. Meta reportedly discussed acquiring <a href="https://www.benzinga.com/markets/equities/25/06/46070157/meta-reportedly-tried-to-buy-ai-video-startup-runway-before-14-billion-scale-ai-bet-report" target="_blank" rel="noreferrer noopener">AI video startup</a> Runway before completing its Scale AI investment.
Meta&#8217;s other AI acquisition pursuits in 2025 included Safe Superintelligence and Perplexity AI.
Meta held $70.23 billion in <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/45117948/meta-q1-earnings-eps-beat-revenue-up-16-ai-approaches-1-billion-monthly-actives-capital-expenditures-forecast-raised" rel="noreferrer noopener">cash and equivalents</a> as of March 31, 2025.
<a target="_blank" href="https://www.benzinga.com/25/05/45144725/meta-analysts-highlight" rel="noreferrer noopener">Wall Street firms</a>, including JPMorgan, Goldman Sachs, and KeyBanc, noted Meta as a leader in the digital ad space backed by strong platform demand, continued momentum in the ad business, and capex investments.
Price Action: META stock was trading higher by 0.75% to $731.52 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46134725/google-cloud-hires-former-oracle-cfo-as-ai-race-heats-up" target="_blank" rel="noreferrer noopener">Google Cloud Hires Former Oracle CFO As AI Race Heats Up</a></li>
</ul>
Photo: Skorzewiak/Shutterstock

Tech

Media

AAPL

GOOGL

MSFT

NVDA

Meta's Play For Voice AI Could Shake Up The Competition

Compass Point analyst Ed Engel maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and raises the price target from $64 to $96.

HOOD

Compass Point Maintains Buy on Robinhood Markets, Raises Price Target to $96

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4458101-1&amp;h=1504814313&amp;u=https%3A%2F%2Fwww.simon.com%2F&amp;a=Simon">Simon</a>&#xAE;, a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations, and Swire Properties, Inc., a leading developer of mixed-use, commercial, and residential properties in Miami, today announced that Simon has acquired Swire Properties' interest in the retail and parking at Brickell City Centre.
Prior to the acquisition, Simon owned a 25%, non-managing interest in the retail at Brickell City Centre, and, following this transaction, will wholly own and manage the asset.

Simon Acquires Swire Properties' Interest In Retail And Parking At Brickell City Centre; Terms Undisclosed

Reuters Cites Tass Saying Putin Says Russia Is Ready For New Round Of Talks In Istanbul

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading around our critical area of 613.46. For bullish continuation, we&#8217;d like to see buyers swiftly take the auction upwards toward 614.75. If momentum sustains above this level, watch for price stability at our key area of 615.74. Holding firm at this zone during normal market conditions could propel SPY upward, targeting 616.31 next. Our upper bullish target for today&#8217;s session stands confidently at 617.21.&nbsp;
On the flip side, should 613.46 break down under selling pressure, bears are likely to press lower, initially challenging 612.68. Further bearish activity could send price down to test the robustness of 611.39. Continued heavy selling will expose 610.63, a significant defensive point. If the market turns notably bearish today, we anticipate an extended downward move toward our lower bear objective at 609.33.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is presently trading close to our pivotal mark of 547.65. Bulls need to firmly secure this level and establish buying interest to advance toward 549.59. Confirmation of strength here could propel the auction higher, testing 550.60. A robust bullish scenario could open the gates to further upside, bringing 553.46 into focus. Our primary bullish objective for QQQ today is at 555.21.&nbsp;
Conversely, if buying stalls around 547.65, bearish momentum may swiftly return, targeting an aggressive push down to 545.14. A continued sell-off could force prices further down to assess strength at 543.22. Persistent bearishness would likely bring about a decisive test of 542.31. Losing this crucial level decisively would see QQQ vulnerable toward our lower bear target at 540.60.
Apple Inc. (AAPL)
Apple shares are currently positioned near our central point of 202.29. Bulls must maintain strong support at this level, looking for momentum to lift prices toward 203.48 initially. Persistent bullishness would likely extend gains to 204.33. A decisive upward thrust could propel Apple towards today&#8217;s bullish ambition at 205.54.&nbsp;
Should selling pressure intensify and Apple fail to defend 202.29 during active trading, bears could target a downward test at 201.29. A sustained bearish auction may see sellers pushing prices down further to 200.53. Continuation of the negative sentiment could expose 199.51. If bearish momentum escalates, Apple&#8217;s price could ultimately move toward our lower bearish objective at 198.79.
Microsoft Corp. (MSFT)
Microsoft is presently auctioning around our critical pivot of 496.90. Bulls will need to hold strong above 498.27 to confidently lift the market toward a pivotal test of 499.79. Solidifying support at this key level during regular market hours could ignite an upward momentum toward 501.34. Sustained bullish activity may carry price action to our high bullish destination at 504.11 today.&nbsp;
If Microsoft loses strength and falls below 496.90, bears are anticipated to push prices lower towards an initial support test at 495.11. Should bearish momentum intensify, the market might test lower ground at 493.62. Persistent selling could send prices down to 491.33, and continued downward force could ultimately lead Microsoft towards our lowest bearish target at 489.88.
NVIDIA Corporation (NVDA)
NVIDIA is currently auctioning near our essential zone of 156.49. For bullish continuation, bulls need to decisively take the auction upward to test and establish support at 158.34. Positive momentum could further propel the price action toward 160.64. If buying strength persists throughout today&#8217;s session, expect a potential move upward toward 162.15. Our ambitious bullish target for NVIDIA today is 164.35.&nbsp;
On the downside, if NVIDIA struggles to hold the support at 156.49, bears are likely to aggressively probe lower levels at 154.64. Persistent bearish strength could lead sellers to push prices even lower towards 153.23. Further weakening would prompt a test of 151.99. Continued bearish pressure may ultimately see NVIDIA reaching down to our lower bear target at 150.32.
Alphabet Inc Class A (GOOGL)
Alphabet shares are currently trading around our critical price level of 174.01. Bulls need to maintain this price as firm support, setting the stage for a push higher toward 175.12. If bullish energy is sustained, Alphabet could continue rallying to our primary upside target at 176.23 today.&nbsp;
If buyers falter and 174.01 fails as support during today&#8217;s trading session, bears will likely step in decisively to probe downward at 172.28. Further bearish momentum may bring the price action to test the critical support at 171.14. An intensified sell-off scenario could drive Alphabet lower toward today&#8217;s bear target at 169.34.
Meta Platforms Inc (META)
Meta is currently auctioning around our pivotal level at 729.50. Bulls should secure strong support here to lift the price action confidently towards the immediate upside target at 733.41. Sustained bullish momentum could then carry the auction higher, bringing 736.12 into play. Extended bullish buying today might push Meta toward our ambitious bullish target at 738.07.&nbsp;
Should Meta fail to maintain the 729.50 support during regular market hours, bears could aggressively target downside pressure initially at 727.04. Continued selling activity may lead to a deeper retracement toward 725.04. A decisive breakdown at this level could set the stage for an intensified bear move towards our lower bear target today at 722.94.
Tesla Inc. (TSLA)
Tesla shares are currently trading around our crucial price point of 327.59. Bullish traders need to push the auction firmly higher toward 333.93 initially. Strong buying activity could propel price significantly upward toward the critical price level of 340.97. Continued bullish activity today might result in testing even higher at 346.64. Strong positive momentum would see Tesla reach towards our ultimate bullish objective today at 350.87.&nbsp;
On the downside, failure to maintain the critical support of 327.59 could trigger bearish action, sending prices swiftly lower to initially test 322.52. Persistent selling pressure would further challenge lower at 315.93. A clear breach of this crucial support could bring about a bearish scenario targeting today&#8217;s low bear level at 312.42.
Final Word: Today&#8217;s session opens with key economic data, including the release of May&#8217;s PCE Price Index, alongside Personal Income and Spending figures, all scheduled at 8:30 AM ET. Concurrently, Canada&#8217;s April GDP data will also be released, providing additional macroeconomic insight. At 10:00 AM ET, traders will receive the Final University of Michigan Sentiment figures for June, along with critical updates to the 1 Year and the 5-10 Year Inflation Outlook. At 11:00 AM ET, attention will shift to the Kansas City Fed Services Activity report, potentially influencing sector-specific sentiment.&nbsp;
Additionally, market participants should closely monitor scheduled remarks from Federal Reserve officials Hammack and Cook at 9:15 AM ET, as their commentary could inject volatility into trading, especially given recent market strength at record-high price levels. Expect an active trading environment, maintain risk management practices, and prioritize capital preservation heading into the weekend. Good luck and trade safely!
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

How To Trade SPY, Top Tech Stocks As Core Inflation Edges Up Above Expectations

Reuters Cites Ifax Saying Putin Says Time And Venue Of Third Round Of Talks With Ukraine Still To Be Agreed

YORKU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Redburn Atlantic analyst Olivier Brochet upgrades Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from Neutral to Buy and raises the price target from $180 to $275.

Upgrades

Redburn Atlantic Upgrades Boeing to Buy, Raises Price Target to $275

IES Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) has outperformed the market over the past 5 years by 50.64% on an annualized basis producing an average annual return of 65.46%. Currently, IES Hldgs has a market capitalization of $5.76 billion. 
Buying $100 In IESC: If an investor had bought $100 of IESC stock 5 years ago, it would be worth $1,254.59 today based on a price of $290.01 for IESC at the time of writing.
<h3>IES Hldgs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751034631_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IESC

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

B of A Securities analyst Ruplu Bhattacharya maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Neutral and lowers the price target from $65 to $61.

CNXC

B of A Securities Maintains Neutral on Concentrix, Lowers Price Target to $61

CNXC stock has given up its prior loss. Concentrix shares were trading lower after the company reported a Q2 adjusted EPS miss and narrowed its FY25 adjusted EPS guidance.

Press Releases

agilon health Sets Date to Report Fourth Quarter and Full Year 2024 Financial Results

Legal

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of agilon health, inc. (NYSE: AGL) and Encourages Long-Term Investors to Contact the Firm

agilon health to Participate in TD Cowen's 45th Annual Health Care Conference

agilon health Reports Fourth Quarter and Full Year Fiscal 2024 Results

agilon health Sets Date to Report First Quarter 2025 Financial Results

agilon health to Participate in BofA Securities 2025 Health Care Conference

agilon health Reports First Quarter 2025 Results

agilon health to Participate in Bernstein's 41st Annual Strategic Decisions Conference

New Research Underscores the Important Role of Value-Based Care (VBC) in Improving Primary Care Access for Traditional Medicare Patients

New Study Finds Senior Patients Managed by Women Physicians in a Value-Based Care (VBC) Model Have Equal or Better Clinical and Quality Outcomes and Less Healthcare Utilization

Addus HomeCare Corporation - Common Stock

Addus HomeCare

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Agilon Health

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL